Antibiotic effectiveness: New challenges in natural resource management

Annual Review of Resource Economics

Volumn 2, Issue , 2010, Pages 125-138

  Herrmann, Markus ^a   Laxminarayan, Ramanan ^b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b RESOURCES FOR THE FUTURE   (United States)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

Antimicrobials; Optimal use; Resistance

Indexed keywords

EID: 79952607396     PISSN: 19411340     EISSN: 19411359     Source Type: Journal    
DOI: 10.1146/annurev.resource.050708.144125     Document Type: Article

References (54)

1. Abboud FM, Waisbren BA. 1959. Correlation between in vitro studies and response to antibiotic therapy in staphylococcic bacteremia. AMA Arch. Intern. Med. 104(2):226-33
2. Aldeyab MA, Monnet DL, López-Lozano JM, Hughes CM, Scott MG, et al. 2008. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillinresistant Staphylococcus aureus: a time-series analysis. J. Antimicrob. Chemother. 62(3):593-600
3. Arrow KJ, Panosian CB, Gelband H, eds. 2004. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington, DC: Inst. Med.
4. Bassett EJ, Keith MS, Armelagos GJ. 1980. Tetracycline-labeled bone from ancient Sudanese Nubia. Science 209:1532-34
5. Bennett PM, Linton AH. 1986. Do plasmids influence the survival of bacteria? J. Antimicrob. Chemother. 18 (Suppl. C): 123-26 (Pubitemid 17174055)
6. Bergstrom CT, Lipsitch M, McGowan JE Jr. 2000. Nomenclature and methods for studies of antimicrobial switching (cycling). Presented at Conf. Antibiot. Resist. Glob. Policies Options, Cambridge, MA
7. Björkman J, Hughes D, Andersson DI. 1998. Virulence of antibiotic-resistant Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 95(7):3949-53 (Pubitemid 28173234)
8. Bonhoeffer S, Lipsitch M, Levin BR. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94(22):12106-11 (Pubitemid 27467850)
9. Boni MF, Smith DL, Laxminarayan R. 2008. Benefits of using multiple first-line therapies against malaria. Proc. Natl. Acad. Sci. USA 105(37):14216-21
10. Bouma JE, Lenski RE. 1988. Evolution of a bacteria/plasmid association. Nature 335(6188):351-52
11. Brown G, Layton DF. 1996. Resistance economics: social cost and the evolution of antibiotic resistance. Environ. Dev. Econ. 1:349-55
12. Cairns RD, Davis GA. 2007. Strike when the force is with you: optimal stopping with application to resource equilibria. Am. J. Agric. Econ. 89(2):461-72 (Pubitemid 47161610)
13. Comins HN. 1977. The management of pesticide resistance. J. Theor. Biol. 65(3):399-420 (Pubitemid 8075286)
14. Comins HN. 1979. Analytic methods for management of pesticide resistance. J. Theor. Biol. 77(2):171-88 (Pubitemid 9152746)
15. Cornes R, Van Long N, Shimomura K. 2001. Drugs and pests: intertemporal production externalities. Jpn. World Econ. 13(3):255-78 (Pubitemid 33623527)
16. De Meza D, Gould JR. 1992. The social efficiency of private decisions to enforce property rights. J. Polit. Econ. 100(3):561-80
17. Duong HA, Pham NH, Nguyen HT, Hoang TT, Pham HV, et al. 2008. Occurrence, fate and antibiotic resistance of fluoroquinolone antibacterials in hospital wastewaters in Hanoi, Vietnam. Chemosphere 72(6):968-73
18. Ellison SF, Hellerstein JK. 1999. The economics of antibiotics: an exploratory study. In Measuring the Prices of Medical Treatments, ed. JE Triplett, 4:118-43. Washington, DC: Brookings Inst.
19. Fischer C, Laxminarayan R. 2004. Monopoly extraction of an exhaustible resource with two markets. Can. J. Econ. 37(1):178-88 (Pubitemid 38492783)
20. Fischer C, Laxminarayan R. 2005. Sequential development and exploitation of an exhaustible resource: Do monopoly rights promote conservation? J. Environ. Econ. Manag. 49(3):500-15 (Pubitemid 40607876)
21. Fischer C, Laxminarayan R. 2010. Managing partially protected resources under uncertainty. J. Environ. Econ. Manag. 59:129-41
22. Herrmann M. 2010. Monopoly pricing of an antibiotic subject to bacterial resistance. J. Health Econ. 29:137-150
23. Herrmann M, Gaudet G. 2009. The economic dynamics of antibiotic efficacy under open access. J. Environ. Econ. Manag. 57(3):334-50
24. Hueth D, Regev U. 1974. Optimal agricultural pest management with increasing pest resistance. Am. J. Agric. Econ. 56(3):543-53
25. John JF Jr, Rice LB. 2000. The microbial genetics of antibiotic cycling. Infect. Control Hosp. Epidemiol. 21 (Suppl.): S22-31
26. Kaier K, Frank U. 2008. An econometric view of the dynamic relationship between antibiotic consumption, hand disinfection and methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 63(3):630-31
27. Kingston W. 2000. Antibiotics, invention and innovation. Res. Policy 29(6):679-710
28. Kristinsson KG. 1997. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microb. Drug Resist. 3(2):117-23 (Pubitemid 27250960)
29. Laxminarayan R. 2002. Antibiotic use in animal agriculture and the economics of resistance: How broad should the scope of antibiotics patents be? Am. J. Agric. Econ. 84:1287-92
30. Laxminarayan R, ed. 2003. Battling Resistance to Antibiotics and Pesticides: An Economic Approach. Washington, DC: RFF
31. Laxminarayan R, Brown GM. 2001. Economics of antibiotic resistance: a theory of optimal use. J. Environ. Econ. Manag. 42(2):183-206 (Pubitemid 34124508)
32. Laxminarayan R, Malani A, Howard D, Smith DL. 2007. Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance. Washington, DC: RFF
33. Laxminarayan R, Over M, Smith DL. 2006. Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? Health Aff. 25(2):325-36 (Pubitemid 43529540)
34. Laxminarayan R, Weitzman ML. 2002. On the implications of endogenous resistance to medications. J. Health Econ. 21(4):709-18
35. Levy SB. 1992. The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. New York: Plenum
36. McGowan JE Jr. 1986. Minimizing antimicrobial resistance in hospital bacteria: Can switching or cycling drugs help? Infect. Control. 7(12):573-76 (Pubitemid 17011976)
37. Mechoulan S. 2007. Market structure and communicable diseases. Can. J. Econ. 40:468-92 (Pubitemid 46784721)
38. Musher DM, Baughn RE, Templeton GB, Minuth JN. 1977. Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J. Infect. Dis. 136(3):360-69 (Pubitemid 8193978)
39. Niederman MS. 1997. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am. J. Respir. Crit. Care Med. 156:1029-31 (Pubitemid 27446505)
40. Office of Technology Assessment (OTA). 1995. Impacts of antibiotic-resistant bacteria. OTA-H-629, OTA, Washington, DC
41. Phelps CE. 1989. Bug/drug resistance: Sometimes less is more. Med. Care 27(2):194-203
42. Rowthorn R, Brown G. 2003. Using antibiotics when resistance is renewable. In Laxminarayan 2003, pp. 42-62
43. Rudholm N. 2002. Economic implications of antibiotic resistance in a global economy. J. Health Econ. 21(6):1071-83 (Pubitemid 35365706)
44. Salant S. 2003. Same infection, same time, same antibiotic In Laxminarayan 2003, pp. 84-93
45. Schrag SJ, Perrot V, Levin BR. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. Biol Sci. 264(1386):1287-91 (Pubitemid 27445226)
46. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, et al. 1997. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N. Engl. J. Med. 337(7):441-46 (Pubitemid 27333044)
47. Smith DL, Levin SA, Laxminarayan R. 2005. Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proc. Natl. Acad. Sci. USA 102(8):3153-58 (Pubitemid 40299931)
48. Sundqvist M, Sjölund M, Runehagen A, Cars H, Abelson-Storby K, et al. 2007. A planned dramatic drop in trimethoprim consumption in a 180, 000 population did not result in a related decrease in trimethoprim resistance in Escherichia coli. Int. J. Antimicrob. Agents 29: S32-33
49. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. 2008. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J. Antimicrob. Chemother. 62(3):601-7
50. Walker B, Barrett S, Polasky S, Galaz V, Folke C, et al. 2009. Looming global-scale failures and missing institutions. Science 325(5946):1345-46
51. Weitzman M. 1976. The optimal development of resource pools. J. Econ. Theor. 12(3):351-64
52. Weitzman ML. 1974. Prices vs. quantities. Rev. Econ. Stud. 61(4):477-91
53. Wilen J, Msangi S. 2003. Dynamics of antibiotic use: ecological versus interventionist strategies to manage resistance to antibiotics. In Laxminarayan 2003, pp. 17-41
54. World Health Organ. (WHO). 2001. The use of antimalarial drugs. Report of a WHO informal consultation. WHO Geneva